membrane attack complex

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

iMAC2, a potent MAC (Membrane Attack Complex) inhibitor, exhibits an IC50 of 28 nM and an LD50 of 15,000 nM, demonstrating significant efficacy in inhibiting MAC. Additionally, iMAC2 effectively suppresses apoptosis by blocking the release of cytochrome c [1].

Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cutting of C5 and preventing the subsequent formation of membrane attack complex, which can be used to study extravascular hemolysis.

Anti-CD59 Antibody is a humanized monoclonal antibody targeting CD59 (Protectin/MAC-IP). CD59 is a GPI-anchored complement regulatory protein widely expressed on cell surfaces. It protects host cells from complement-mediated lysis by binding to complement components C8 and C9, thereby preventing the final assembly of the Membrane Attack Complex (MAC/C5b-9). CD59 is often overexpressed in various solid tumors and hematologic malignancies, enabling tumor cells to evade immune surveillance. This antibody specifically binds to CD59, blocking its inhibition of MAC assembly to restore tumor cell sensitivity to complement and induce potent Complement-Dependent Cytotoxicity (CDC). It serves as a critical tool for investigating tumor immune evasion and developing enhanced complement-based immunotherapies.

C5 Protein (human) is a naturally glycosylated polypeptide composed of two disulfide-linked chains. It is essential for the formation of the membrane attack complex (MAC) and is activated via all three pathways of complement activation.